Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 18/20 | 0.58 |
| ▸ | PRKCD | Q05655 | 9/20 | 0.58 |
| ▸ | LYN | P07948 | 1/20 | 0.58 |
| ▸ | PRKCH | P24723 | 1/20 | 0.46 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5521585 | 0.81 | PRKCQ (0.66) | PRKCQPRKCDLYNPRKCHPRKCE | |
| SCHEMBL5518112 | 0.78 | PRKCQ (0.60) | PRKCQPRKCDLYNPRKCHPRKCE | |
| SCHEMBL5526945 | 0.78 | PRKCQ (0.58) | PRKCQPRKCDLYNPRKCHPRKCE | |
| SCHEMBL1146269 | 0.78 | PRKCQ (0.54) | PRKCQPRKCDLYNPRKCHPRKCE | |
| SCHEMBL4948150 | 0.77 | PRKCQ (0.58) | PRKCQPRKCDLYNEGFR | |
| SCHEMBL4951713 | 0.77 | PRKCQ (0.72) | PRKCQPRKCDLYNPRKCHPRKCE | |
| SCHEMBL4950801 | 0.77 | PRKCQ (0.72) | PRKCQPRKCDLYNPRKCHPRKCE | |
| SCHEMBL5525018 | 0.76 | PRKCQ (0.55) | PRKCQPRKCDLYNPRKCHPRKCE | |
| Hydrochloric Acid SCHEMBL4952340 | 0.76 | PRKCQ (0.71) | PRKCQPRKCDLYNPRKCHPRKCE | |
| SCHEMBL4951604 | 0.73 | PRKCQ (0.70) | PRKCQPRKCDLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937690-A1 | THIENO[2,3-B]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070082880-A1 | Thieno [2,3-B] pyridine-5-carbonitriles as protein kinase inhibitors | WYETH | 2007-04-12 | — | — | US | disclosed |
| WO-2007038519-A1 | THIENO[2,3-B]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082880-A1 | Thieno [2,3-B] pyridine-5-carbonitriles as protein kinase inhibitors | MAP4K2, CNKSR1, MAP3K1 | PRKCQ 286/4885PRKCD 356/4885LYN 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.